



INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE

NEW METHOD DEVELOPMENT AND VALIDATION OF UV-SPECTROPHOTOMETER FOR THE ESTIMATION OF PALIPERIDONE IN BULK AND PHARMACEUTICAL DOSAGE FORM

INJAVARAPU DIVYA, UTTAM PRASAD PANIGRAHY

Department of Pharmaceutical Analysis and Quality Assurance, Malla Reddy College Of Pharmacy, Maisammaguda,
Secunderabad, India

Accepted Date: 10/03/2014; Published Date: 27/04/2014

Abstract: Paliperidone is a dopamine antagonist of the atypical antipsychotic class of medications. Simple, economic, sensitive, reproducible and rapid UV-Spectrophotometric method have been developed and validated for the determination of Paliperidone (PP) in pharmaceutical dosage forms and in bulk drug. The absorption maxima was found to be at 235 nm in methanol and shows linearity over the concentration range of 1-30 μ g ml⁻¹ with regression equation $0.032x + 0.011$ ($r^2 = 0.999$) and $0.0312x + 0.007$ ($r^2 = 0.999$) at 278nm. The proposed method can be successfully applied for the determination of Paliperidone in dosage forms. The methods were validated as per the ICH guidelines.

Keywords: Paliperidone, spectroscopy, Validation, ICH guidelines



PAPER-QR CODE

Corresponding Author: MS. INJAVARAPU DIVYA

Access Online On:

www.ijprbs.com

How to Cite This Article:

Injavarapu Divya, IJPRBS, 2014; Volume 3(2): 106-125

INTRODUCTION

Paliperidone (9-hydroxyrisperidone) is a major active metabolite of risperidone and is indicated for the acute and maintenance treatment of schizophrenia. Paliperidone is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives. Literature survey revealed that LC-MS methods, HPTLC, HPLC, UPLC methods were developed for the analysis of Paliperidone in different solvents and UV-spectrophotometric methods were available which developed in 0.1N HCl. In the present study a simple, rapid, precise and accurate UV-spectrophotometric method has been developed for the determination of Paliperidone in pharmaceutical dosage forms and validated as per the ICH guidelines.




Figure1. Chemical Structure of Paliperidone

MATERIALS AND METHODS

Instrumentation

A double beam UV-VIS spectrophotometer (UV-1800, Shimadzu, Japan) connected to computer loaded with spectra manager software UV Probe was employed with spectral bandwidth of 1nm and wavelength accuracy of ± 0.3 nm with a pair of 10 mm matched quartz cells. All weights were taken on electronic balance (Contech).

Chemicals and reagents

Methanol used as diluent. Drug sample of Paliperidone was given as a gift sample by Natco Pharma limited, Hyderabad (India) was used as such without further purification. Tablets of Paliperidone (PALIDO) were procured from local market.

Preparation of Standard Stock Solution:

The standard solution of Paliperidone was prepared by dissolving accurately about 100 mg of the Paliperidone with Methanol in a 100 ml volumetric flask and sonicated for 20 mins. This stock solution was further diluted with methanol as per the requirement.

Preparation of Sample Solution:

Twenty tablets of Paliperidone were taken and into a fine powder of the tablets and the powder equivalent to 10 mg of Paliperidone was weighed accurately and transferred into a 100 ml standard volumetric flask. The contents were dissolved in methanol and sonicated for 30 Minutes. This entire solution was filtered through 0.45 micron Whatmann filter paper (No. 41) and the final solution was made with methanol to get the solution of 1000 $\mu\text{g}/\text{ml}$. This solution was further diluted with methanol as per the requirement.

Procedure:

The drug solution was scanned (200-400 nm) against reagent blank i.e. methanol and the absorption spectrum was recorded. The absorption maximum (λ_{max}) was observed at 235 nm and 278nm and the absorbance of a series of solutions (1-30 $\mu\text{g ml}^{-1}$) was recorded at that λ_{max} . A graph was plotted by taking the concentration of the drug solutions on the x-axis and the corresponding absorbance values on the y-axis which was shown in figures 4 and 5.

Assay procedure for the commercial formulations (Tablets):

Paliperidone is available as tablets of extended release containing 3mg of Paliperidone. Paliperidone is available in the local market with brand names PALIDO (3 mg, TORRENT Pharmaceuticals, India). The sample solution which was prepared earlier was taken and further diluted as per the requirement. A series of solutions were prepared were scanned and the corresponding absorbance values were recorded. The % recovery was calculated from the regression equations obtained from the calibration curves which was shown in table 1 and figures 2 and 3.

Table No 1. Assay of commercial formulations

Sample no	Formulation	Label claim (mg)	Amount found (mg)	% Recovery
1	Tablets	3	3.0078	100.26
2	Tablets	3	3.0048	100.16




Figure2. Absorption spectrum of standard and sample drug (10µg/ml)




Figure3. Absorption spectrum of standard and sample drug (20µg/ml)

2. Accuracy studies:

The accuracy of the method, recovery studies were carried out by adding different amounts (80%, 100% and 120%) of bulk samples of Paliperidone within the linearity range were taken and added to the pre-analyzed formulation of concentration 10µg/ml. From that percentage recovery values were calculated. The results were within the range and were found to be highly accurate which was shown in table 2 and 3.

Table No 2 Accuracy studies (at λ_{235nm})

Spiked level (%)	Formulation Conc (µg/ml)	Pure Drug (µg/ml)	Conc	% Recovery	% Mean recovery	SD	%RSD
80	10	8		100.16	100.21	0.244	0.243
	10	8		100			
	10	8		100.48			
100	10	10		100.77	100.51	0.323	0.321
	10	10		100.62			
	10	10		100.15			
120	10	12		99.71	100.69	0.985	0.978
	10	12		100.70			
	10	12		101.68			

Table No 3 Accuracy studies (at $\lambda_{278\text{nm}}$)

Spiked level (%)	Formulation Conc ($\mu\text{g/ml}$)	Pure Drug ($\mu\text{g/ml}$)	Conc	% Recovery	% Mean recovery	SD	%RSD
80	10	8		100.94	100.67	0.292	0.290
	10	8		100.72			
	10	8		100.36			
100	10	10		101.53	101.14	0.359	0.354
	10	10		100.82			
	10	10		101.08			
120	10	12		100.92	100.93	0.285	0.282
	10	12		100.66			
	10	12		101.23			

2. Precision

Precision of an analytical method is usually expressed as standard deviation or relative standard deviation. The standard deviation and % relative standard deviation are calculated from statistical formula. The standard deviation and relative standard deviation for the absorbance values were calculated from statistical formula which was shown in tables 4 and 5.

A). Repeatability

Table No 4 Repeatability studies (at $\lambda_{235\text{nm}}$)

Concentration [$\mu\text{g/ml}$]	Absorbance at235nm	Absorbance Mean	SD	%RSD
10	0.342	0.342	0.001	0.306
10	0.343			
10	0.343			
10	0.344			
10	0.341			
10	0.342			
10	0.342			

Table No 5 Repeatability studies (at $\lambda_{278\text{nm}}$)

Concentration [$\mu\text{g/ml}$]	Absorbance at279nm	Absorbance Mean	SD	%RSD
10	0.340	0.341	0.001	0.399
10	0.341			
10	0.344			
10	0.342			
10	0.341			
10	0.342			
10	0.342			

B) Inter day Precision

To check the reproducibility of the method, the same procedure was followed as that of precision of the method on the next day. Absorbance of each solution was scanned and the spectra were recorded. The standard deviation and relative standard deviation for the absorbance values using the statistical formula and the results were shown in tables 6 and 7.

Table No 6 Interday precision (at $\lambda_{235\text{nm}}$)

Sample no	Inter day	
1	0.363	Mean=0.364 S.D=0.0029 %RSD=0.808
2	0.364	
3	0.365	
4	0.362	
5	0.366	
6	0.362	
7	0.366	
8	0.371	

Table No 7 Interday precision (at $\lambda_{278\text{nm}}$)

Sample no	Inter day	
1	0.358	
2	0.359	
3	0.355	Mean=0.358 S.D=0.0015 %RSD=0.445
4	0.358	
5	0.360	
6	0.358	
7	0.360	
8	0.359	

C). Intraday Precision

To check the reproducibility of the method, the same procedure was followed as that of precision of the method on the same day. Absorbance of each solution was scanned and the spectra were recorded. The standard deviation and relative standard deviation for the absorbance values using the statistical formula and the results were shown in tables 8 and 9.

Table No 8 Intraday precision (at $\lambda_{235\text{nm}}$)

Sample no	Intra day	
1	0.360	
2	0.359	
3	0.355	Mean=0.358 S.D=0.0019 %RSD=0.537
4	0.359	
5	0.359	
6	0.360	
7	0.360	
8	0.356	

Table No 9 Intraday precision (at $\lambda_{278\text{nm}}$)

Sample no	Intra day	
1	0.365	
2	0.363	
3	0.365	Mean=0.365
4	0.361	S.D=0.0028
5	0.371	%RSD=0.784
6	0.366	
7	0.365	
8	0.366	

3. Specificity: The analyte was assessed in the presence of the components and it was found that there was no interaction with the analyte.




Figure 4. Specificity

4. Limit of Detection and Limit of Quantification

The LOD and LOQ were calculated based on the standard deviation of the response and the slope of the constructed calibration curve, as described in International Conference on Harmonization guidelines Q2 (R1) was shown in table no 18.

5. Linearity:

The linearity of the analytical method is determined by mathematical treatment of test results obtained by analysis of samples with analyte concentrations across the claimed range. Absorbance was plotted graphically as a function of drug concentration. Absorbance of each solution was scanned and the spectra were recorded. Calibration curve was plotted for both the drugs individually using the absorbance obtained at the different concentration levels. The linearity of the drug Paliperidone was observed at 1-30µg/ml was shown in table 10 and 11 and figure 5 and 6.




Figure 5. Linearity graph (at $\lambda_{235\text{nm}}$)

Table No 10 linearity (at $\lambda_{235\text{nm}}$)

Conc. (µg/ml)	Absorbance (235nm)
1	0.044
2	0.068
4	0.157
5	0.180
8	0.278
10	0.341
20	0.645
30	0.996

Table No 11 linearity (at $\lambda_{278\text{nm}}$)

Conc. ($\mu\text{g/ml}$)	Absorbance (278nm)
1	0.042
2	0.05
4	0.147
5	0.178
8	0.261
10	0.327
20	0.643
30	0.973




Figure6. Linearity graph (at $\lambda_{278\text{nm}}$)

6. Range: The range of an analytical procedure is the interval between the upper and lower concentration (amounts) of analyte in the sample (including these concentrations) for which it has been demonstrated that the analytical procedure has a suitable level of precision, accuracy and linearity. The range was found between 1-30 $\mu\text{g/ml}$.

7. Robustness:

The Robustness of the method was determined by making slight changes in the experimental conditions such as the temperature and scanning the samples maintained at room temperature and cooled to 18°C as shown in table 12 and 13.

Table No 12 Robustness (at $\lambda_{278\text{nm}}$)

Sample no	Room temperature (Abs)		Cooling temperature 18°C (Abs)	
1	0.360		0.360	
2	0.359		0.356	
3	0.355	Mean=0.358	0.358	Mean=0.357
4	0.359	S.D=0.00186	0.355	S.D=0.00242
5	0.359	%RSD=0.519	0.361	%RSD= 0.677
6	0.360		0.356	

Table No 13 Robustness (at $\lambda_{235\text{nm}}$)

Sample no	Room temperature (Absorbance)		Cooling temperature at 18°C (Absorbance)	
1	0.365	Mean=0.365	0.387	Mean=0.385
2	0.363	S.D=0.0033	0.385	S.D=0.0026
3	0.365	%RSD=0.923	0.385	%RSD 0.689
4	0.361		0.381	
5	0.371		0.389	
6	0.366		0.385	

8. Ruggedness:

The ruggedness of the method was determined by carrying out the experiment on different instrument like Lab India double beam UV- spectrophotometer and Shimadzu UV-Visible spectrophotometer and by different analysts. The results were analyzed and was shown in table 14.

Table No 14 Ruggedness by two different instruments

Lab India double beam UV- spectrophotometer					Shimadzu UV-Visible spectrophotometer					
Sample no	Absorbance				Absorbance					
	235nm	278nm			235nm	278nm			235nm	278nm
1	0.342	0.339			0.342	0.339				
2	0.343	0.331	Mean	0.342	0.336	0.344	0.340	Mean	0.342	0.340
3	0.343	0.336	S.D	0.001	0.004	0.343	0.336	S.D	0.001	0.004
4	0.344	0.340	%RSD	0.306	1.21	0.342	0.336	%RSD	0.306	1.17
5	0.341	0.331			0.343	0.349				
6	0.342	0.339			0.341	0.340				

Table No 15 Ruggedness by two different analyst

Analyst-1					Analyst-2					
Sample no	Absorbance				Absorbance					
	235nm	278nm			235nm	278nm			235nm	278nm

	m	m		m	m	m	m		m	m
1	0.343	0.339				0.341	0.342			
2	0.341	0.338	Mean	0.341	0.339	0.340	0.339	Mean	0.341	0.340
3	0.344	0.336	S.D	0.0014	0.002	0.339	0.338	S.D	0.0014	0.001
4	0.340	0.338	%RSD	0.430	0.791	0.342	0.340	%RSD	0.414	0.415
5	0.341	0.344				0.343	0.341			
6	0.342	0.339				0.341	0.340			

The ruggedness was performed by taking the percentage difference in the means of assay results between the ruggedness parameters of two different instruments and two different analysts from the above table 14 and 15.

Table No 16 Mean Assay of Ruggedness

Sample no	Different Instrument-1				Different Instrument-2				Mean	Mean
	%Assay		%Assay		%Assay		%Assay			
	235n m	278n m			235n m	278n m			235n m	278n m
1	100.26	100.26			100.26	99.97				
2	100.26	99.97	Mean	100.21	100.49	100.55	100.85	Mean	100.35	100.45
3	99.39	100.26	S.D	0.502	0.419	100.85	101.1	S.D	0.302	0.466
4	99.97	100.55	%RSD	0.500	0.417	99.97	100.55	%RSD	0.301	0.464

5	100.55	100.85	100.26	100.26
6	100.85	101.1	100.26	99.97

	At 235nm	At 278nm
Over All Mean	100.28	100.47
Mean S.D	0.402	0.442
Mean %R.S.D	0.400	0.439

Percentage Difference of Mean Calculations: (at λ_{235nm})

$$\% \text{ Difference of means} = \frac{(\text{Mean\% assay of Instrument-1}) - (\text{Mean\% assay Instrument-2})}{\text{Mean\% assay Instrument-1}}$$

$$= \frac{100.21 - 100.35}{100.21} = -0.0013$$

Percentage Difference of Mean Calculations: (at λ_{278nm})

$$\% \text{ Difference of means} = \frac{(\text{Mean\% assay of Instrument-1}) - (\text{mean\% assay Instrument-2})}{\text{Mean\% assay Instrument-1}}$$

$$= \frac{100.49 - 100.45}{100.49} = 0.0003$$

Table No 17 Mean Assay of Ruggedness

Sample no	Analyst-1				Analyst-2			
	%Assay		%Assay		%Assay		%Assay	
	235n	278n	235n	278n	235n	278n	235n	278n
	m	m	m	m	m	m	m	m

1	99.97	100.8			100.55	100.4			
2	100.26	101.4	Mean	100.01	101.15	100.26	100.5	Mean	100.06 100.66
3	100.26	101.7	S.D	0.339	0.516	99.39	100.7	S.D	0.396 0.258
4	99.39	100.5	%R.S.D	0.338	0.510	99.97	100.8	%R.S.D	0.395 0.256
5	100.26	101.7			100.26	101.1			
6	99.97	100.8			99.97	100.5			

	At 235nm	At 278nm
Over All Mean	100.03	100.90
Mean S.D	0.367	0.387
Mean %R.S.D	0.366	0.383

Percentage Difference of Mean Calculations: (at λ_{235nm})

% Difference of means = $\frac{(\text{Mean\% assay of Analyst-1}) - (\text{Mean\% assay Analyst-2})}{\text{Mean\% assay Analyst-1}}$

$$= \frac{100.01 - 100.06}{100.01} = 0.0004$$

Percentage Difference of Mean Calculations (at λ_{278nm})

% Difference of means = $\frac{(\text{Mean\% assay of Analyst-1}) - (\text{Mean\% assay Analyst-2})}{\text{Mean\% assay Analyst-1}}$

$$= \frac{101.15 - 100.66}{101.15}$$

101.15

=0.0048

9. Forced Degradation Study

Drug samples were subjected to alkaline hydrolysis using 0.1N NaOH, Acid hydrolysis using 0.1N HCl, and peroxide oxidation using 3% H₂O₂, treated samples were scanned and their respective spectra were recorded and the Changes in absorbance value were recorded and the results were shown in table 17 and the absorption spectra were shown in figures 7,8,9,10.




Figure7. 0.1N HCl (Acidic condition)




Figure8 0.1N NaOH (Basic condition)




Figure9 3% H_2O_2 (Oxidation)




Figure10 Water (Neutral condition)

Table No 18 Forced degradation studies of Paliperidone

Degradation parameters	Absorbance		Concentration ($\mu\text{g/ml}$)		%Drug Decomposed		Degradation time
	235nm	278nm	235nm	278nm	235nm	278nm	
Standard drug	0.341	0.327	10	10	0	0	
Acid degradation (0.1N HCl)	0.610	0.427	17.88	13.05	78.88	30.5	90mins
Alkali degradation (0.1N NaOH)	0.467	0.443	13.69	13.54	36.95	35.4	60mins
Peroxide degradation (3% H_2O_2)	1.008	0.480	29.56	14.07	95.6	47	40mins
Neutral conditions (Water)	0.507	0.476	14.86	14.55	48.68	45.5	40mins

RESULTS AND DISCUSSION

Beer Lambert's law was obeyed over the concentration range 1–30 μgml^{-1} in the proposed method. The linear regression equations were found to be $y = 0.032x + 0.011$ ($r^2 = 0.999$) at 235nm and $0.0312x+0.007$ ($r^2=0.999$) at 279nm. The %RSD values in precision studies were found to be 0.537 at 235nm and 0.783 at 278nm which are less than 2% indicating that the method is more precise. The % RSD values in accuracy studies were also found to be less than 2% indicating that the method is more accurate. The degradation studies were performed using 0.1N HCl, 0.1N NaOH, 3% H_2O_2 and water in acidic, alkaline, peroxidation and neutral conditions respectively. The drug has been totally degraded in peroxidation condition when compared to the other acid, alkaline and neutral conditions.




Figure11 Overlay spectra

Table No 19 optical characteristics of Paliperidone

PARAMETERS	METHOD	
λ_{max} (nm)	235	278
Beers law limit $\mu\text{g/ml}$	1-30	1-30
Molar absorptivity ($\text{L mol}^{-1}\text{cm}^{-2}$)	3.41×10^4	3.27×10^4
Correlation coefficient (r^2)	0.999	0.999
Regression equation ($y=mx+c$)	$0.032x+0.011$	$0.0312x+0.007$
Slope (m)	0.032	0.0312
Intercept(c)	0.011	0.007

Accuracy	99.71-101.68	100.36-101.53
Precision (%RSD)	0.537	0.784
LOD ($\mu\text{g/ml}$)	0.297	0.299
LOQ ($\mu\text{g/ml}$)	0.901	0.480
Sandell's sensitivity ($\mu\text{ cm}^{-2}/0.001$ absorbance units)	0.0293	0.03058
90 % Confidence limits	(+)0.364 (-) 0.268	(+)1.199 (-) 0.856
95% Confidence limits	(+)0.313 (-) 0.217	(+)1.0303 (-)0.691

ACKNOWLEDGEMENT

The authors are grateful to Malla Reddy college of Pharmacy for providing necessary facilities to carry out the research work and to NATCO Pharmaceuticals., India for providing the gift sample of the drug.

REFERENCES:

1. Rashmin B. Patel et al. HPTLC method development and validation: Quantification of paliperidone in formulations and *in vitro* release study, *Anal. Methods*, 2010, 2: 525-531
2. Sanjay A. Jadhav, Shashikant B. Landge et al. Stress Degradation Behavior of Paliperidone, an Antipsychotic Drug, and Development of Suitable Stability-Indicating RP-LC Method Chromatography Research International, 2011.
3. Khemchand Dadare, N. C. Khatri et al. Application of RP-RRLC methods for estimation of paliperidone in tablet dosage forms Pant Journal of Chemical and Pharmaceutical Research, 2012, 4(6):3154-3157
4. Sunil R Dhaneshwar, Shubhangi et al. Validated High Performance Thin Layer Chromatographic Method for Quantitation of Paliperidone in the Presence of Degradation Products Formed Under ICH Recommended Stress, Conditions journal of pharmaceutical and biomedical sciences, 2012, 16 (15):2012
5. S. L Mendez, Andreas; Pedro E. et al. HPLC Quantitative Determination of Paliperidone in OROS® Tablets by Derivative Spectrophotometric [Current Analytical Chemistry](#) 2014,10 (1): 158-165

6. Nihar Ranjan Das, G Vidyasagar, Analytical Method Development Of Telmisartan And Paliperidone As Bulk Drug And Formulation Using Chromogenic Reagents " Inventi Rapid: Pharm Analysis & Quality Assuranc 2013
7. Sireesha Kancharla, G.S. Pavan, et al. Development and Validation Of Paliperidone In Bulk And Pharmaceutical Formulation By Rp-Hplc International Journal of Biological & Pharmaceutical Research. 2013; 4(6): 412-416
8. Rashmin b. patel [mrunali r. patel](#), et al. HPTLC method development and validation: Quantification of paliperidone in formulations and *in vitro* release study. Anal. Methods, 2010, 2: 525-531.
9. P.V.V. Satyanarayana, Alavala Siva Madhavi. Lcms Method Development and Validation Of Paliperidone In Formulation Dosage, Research Desk, 2012, 1(1).1
10. Sireesha Kancharla, Bonthu Satyanarayana Deepthi et.al. Development and Validation Of Paliperidone In Bulk And Pharmaceutical Formulation By Uv Spectroscopy IJPRBS, 2013; 2(4): 230.
11. Kanubhai Trivedi, Rakshit; Jain, et al. A Rapid, Stability Indicating RP-UPLC Method for Determination of Paliperidone Palmitate in a Depot Injectable Formulation. Journal of Applied Pharmaceutical Science.2013, 3(7):87-92.
12. Rakshit Kanubhai Trivedi, Ravikumar Jupudi, et al. A Validated Spectrophotometric Method For Determination of Paliperidone Palmitate in Bulk Drug and Its Pharmaceutical Dosage Form. journal of pharmacy and pharmaceutical sciences 2013 2(3).
13. Dadare, Khemchand; Khatri, N. C.; Pant, et al. Application of RP-RRLC methods for estimation of paliperidone in tablet dosage forms. Journal of Chemical & Pharmaceutical Research. 2012, 4(6), 3154-3157.